The whistleblower report centers on the manipulation of Adjusted EBITDA, a metric critical to both the company’s performance reporting and executive compensation packages. According to the complaint, management engaged in a practice of shifting operational costs into capital expenditure accounts to obscure the firm's true financial health. Following the disclosure, the company's stock price dropped $4.02, closing at $20.03 per share.
Pomerantz LLP is currently evaluating potential securities fraud claims on behalf of affected shareholders. The firm, which specializes in corporate and antitrust litigation, has invited investors to provide information regarding their holdings as they assess whether officers or directors violated their fiduciary duties. This investigation seeks to determine the extent of the alleged misconduct and its impact on the company's public disclosures.
Comments (0)
No comments yet. Be the first!